Intervacc AB (publ) (IVACC.ST)
Intervacc AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Hägersten, AB, SE. The stock last traded at $0.96, down 0.10% on the session, giving a market capitalisation of $326.5M. Its beta of 0.15 implies it has historically moved less than the broad market.
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Intervacc AB (publ) is most often compared with the following Healthcare names: